Why this chain matters

Myriad Genetics, Inc. (MYGN) has a mapped ChainSifter graph with 14 supplier links and 14 customer links. That makes it useful for investors trying to understand who benefits when MYGN performs well, and who may be exposed if demand or execution weakens.

The point is not to treat every edge as equal. The useful signal is the shape of the network: named suppliers, named customers, confidence levels, and filing language that shows where business dependence may sit.

Supplier exposure

The supplier side shows the companies and entities most directly tied to MYGN's operating base. Higher-confidence links deserve the first review because they are the relationships most likely to matter when margins, production, procurement, or delivery timelines change.

  • Werewolf Therapeutics, Inc. (HOWL) - confidence 72%.
  • Immunome, Inc. (IMNM) - confidence 72%.
  • Kodiak AI, Inc. (KDK) - confidence 72%.
  • Seres Therapeutics, Inc. (MCRB) - confidence 72%.
  • Pharvaris N.V. (PHVS) - confidence 72%.
  • Prime Medicine, Inc. (PRME) - confidence 72%.
  • Sana Biotechnology, Inc. (SANA) - confidence 72%.
  • Scholar Rock Holding Corporation (SRRK) - confidence 72%.

Customer and demand signals

The customer side is where revenue concentration and downstream demand risk usually show up first. If a customer relationship is central to the graph, a change in that customer's spending or inventory cycle can move through the chain quickly.

  • CytomX Therapeutics, Inc. (CTMX) - confidence 72%.
  • Seres Therapeutics, Inc. (MCRB) - confidence 72%.
  • Veracyte, Inc. (VCYT) - confidence 72%.
  • Kodiak AI, Inc. (KDK) - confidence 72%.
  • Metagenomi Therapeutics, Inc. (MGX) - confidence 72%.
  • Prime Medicine, Inc. (PRME) - confidence 72%.
  • Vor Biopharma Inc. (VOR) - confidence 72%.
  • Opus Genetics, Inc. (IRD) - confidence 72%.

Filing evidence

ChainSifter is most useful when the map is tied back to source language. These excerpts are the evidence trail behind the graph and should be reviewed before treating a relationship as investable signal.

  • Myriad Genetics, Inc.: Reciprocal relationship from CTMX graph: ccess to our facility and initiate a work-from-home program limiting onsite activity to a substantially reduced level of laboratory research activities. Although we gradually increased our laboratory research activities
  • Werewolf Therapeutics, Inc.: Reciprocal relationship from HOWL graph: any jurisdiction that we seek patent protection may diminish our ability to protect our inventions, maintain and enforce our intellectual property rights; and, more generally, may affect the value of our intellectual pr
  • Immunome, Inc.: Reciprocal relationship from IMNM graph: ay in the future cause a security incident or other interruption that could result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access
  • Kodiak AI, Inc.: Reciprocal relationship from KDK graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from KDK graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from KDK graph: Reciprocal relationship from MYGN graph: Reciprocal relati
  • Seres Therapeutics, Inc.: Reciprocal relationship from MCRB graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from MCRB graph: , there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or other pr

Who benefits and who is exposed

If Myriad Genetics, Inc. outperforms, the first-order beneficiaries are the suppliers with high-confidence relationships and the customers that rely on the company's output. If MYGN struggles, the exposed names are the counterparties with fewer alternate channels or relationships that appear repeatedly in the filing trail.

This is the practical use case: map the counterparties, separate confirmed relationships from weak ones, and watch for new filings that change the direction or concentration of exposure.

The most important follow-up is not simply whether a counterparty appears once. It is whether the same relationship persists across filings, appears in risk-factor language, or connects to revenue, procurement, capacity, or delivery obligations. Those are the details that turn a graph edge into investable supply chain intelligence.

How to read the signal

A compact graph can still be useful when the named counterparties are specific and the evidence is direct. Investors should read each relationship as a working hypothesis about exposure, then compare it with revenue mix, segment performance, margin pressure, and management commentary in the next filing cycle.

The strongest signals usually have three traits: a named counterparty, a clear commercial role, and repeated language over time. A one-off mention is weaker. A relationship tied to manufacturing, purchasing, licensing, distribution, or customer concentration is stronger because it can affect revenue durability, operating leverage, or execution risk.

For Myriad Genetics, Inc., the current graph gives analysts a starting map rather than a final conclusion. The supplier side points to operating dependencies. The customer side points to demand dependencies. The evidence trail shows which edges deserve deeper work before they are used in a trade or portfolio risk review.

What to watch

  • New or removed supplier names in future filings.
  • Customer concentration language that points to revenue dependence.
  • Confidence changes in the ChainSifter graph as new evidence is processed.